1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Actinogen Medical Limited

Actinogen Medical Limited

ACW.AX
Actinogen Medical LimitedAU flagAustralian Securities Exchange
0.04
AUD
- -
- -
137.53MMarket Cap
Actinogen Medical Limited
ACW.AX
(Australian Securities Exchange)

Recent

price

0.04

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.03
-0.03
-0.04
- -
- -
-0.01
-0.01
- -
-0.01
-0.01
- -
- -
-0.01
-0.01
-0.01
- -
Basic EPS, GAAP
-0.03
-0.03
-0.02
- -
- -
-0.01
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.15
-0.16
-0.11
-0.1
-0.02
0.02
0.01
0.01
0.01
0.01
- -
0.01
0.01
0.01
0.01
- -
Book Value per Share
0.05
0.04
0.01
- -
0.01
0.02
0.01
0.01
0.02
0.01
0.01
0.01
0.01
0.01
0.01
0.01
Tangible Book Value per Share
25
24
39
48
164
444
653
656
759
1,187
1,204
1,483
1,812
1,902
2,174
2,980
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-2,076.42
-1,786.94
-2,152.49
- -
-2,958.88
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
-1
-2
- -
- -
-5
-4
-3
-6
-10
-5
-4
-9
-11
-13
-15
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-1,523.35
-1,262.12
-2,965.66
- -
-2,201.11
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
1
1
- -
- -
1
10
7
5
13
12
7
14
19
11
18
16
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
1
1
- -
- -
1
15
12
9
17
16
11
17
22
13
20
18
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
-44.26
-64.31
-85.18
-98.99
-87.06
-52.17
-62.04
-74.09
-92.16
-127.73
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.73%
17.31%
-6.91%
Free Cash Flow
- -
261.77%
365.77%
Net Income, GAAP
22.61%
32.7%
12.94%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.01
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Kancera AB (publ) (KAN.ST)
Physiomics Plc (PYC.L)
VistaGen Therapeutics, Inc. (VTGN)
Codiak BioSciences, Inc. (CDAK)
Wuhan Keqian Biology Co.,Ltd (688526.SS)
Citius Pharmaceuticals, Inc. (CTXR)
Business
Actinogen Medical Limited is an Australian biotechnology firm dedicated to developing treatments for a range of neurological and neuropsychiatric conditions linked to imbalanced brain cortisol levels. The company is advancing Xanamem (emestedastat), an oral small molecule that selectively inhibits the 11β-HSD1 enzyme to modulate cortisol within the brain. Xanamem is currently undergoing a pivotal Phase 2b/3 clinical trial for Alzheimer's disease in Australia and the United States, targeting mild to moderate forms of the condition. Further, Xanamem has shown positive Phase 2a results for cognitive impairment in Major Depressive Disorder and is also being explored for its potential in Fragile X Syndrome. Established in 1999, the company adopted its current name in November 2015 and operates from Sydney, Australia.